$ATYR
aTyr Pharma Inc

2022 Q3 Form 10-Q Financial Statement

#000095017022017401 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.625M $3.449M $2.685M
YoY Change 39.96% 23.62% 16.74%
% of Gross Profit
Research & Development $9.867M $9.135M $5.955M
YoY Change 92.04% 19.33% 26.7%
% of Gross Profit
Depreciation & Amortization $49.00K $63.00K $108.0K
YoY Change -60.16% -49.19% -16.92%
% of Gross Profit
Operating Expenses $13.49M $12.58M $8.640M
YoY Change 74.59% 20.48% 23.61%
Operating Profit -$13.49M -$12.58M
YoY Change 74.59% 20.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $247.0K $163.0K $79.00K
YoY Change 318.64% 207.55% 690.0%
Pretax Income -$13.25M -$12.42M -$8.561M
YoY Change 72.71% 19.52% 73.3%
Income Tax
% Of Pretax Income
Net Earnings -$13.20M -$12.40M -$8.559M
YoY Change 72.12% 19.33% 73.61%
Net Earnings / Revenue
Basic Earnings Per Share -$0.46 -$0.44
Diluted Earnings Per Share -$0.46 -$0.44 -$306.9K
COMMON SHARES
Basic Shares Outstanding 28.63M 28.06M
Diluted Shares Outstanding 28.66M 28.06M

Balance Sheet

Concept 2022 Q3 2022 Q2 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $77.37M $88.55M $107.9M
YoY Change -33.5% 100.98% 240.53%
Cash & Equivalents $18.36M $8.484M $2.336M
Short-Term Investments $59.02M $80.07M $105.6M
Other Short-Term Assets $6.386M $4.375M $5.223M
YoY Change 25.49% 93.93% 190.17%
Inventory
Prepaid Expenses $6.386M $4.375M $5.223M
Receivables
Other Receivables $873.0K $426.0K $435.0K
Total Short-Term Assets $84.63M $93.36M $113.6M
YoY Change -30.38% 101.17% 219.63%
LONG-TERM ASSETS
Property, Plant & Equipment $1.275M $558.0K $543.0K
YoY Change -41.67% -77.09% -39.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $169.0K $175.0K $158.0K
YoY Change 6.96% 15.13% -25.82%
Total Long-Term Assets $11.42M $2.661M $1.968M
YoY Change 387.29% 2.82% -38.4%
TOTAL ASSETS
Total Short-Term Assets $84.63M $93.36M $113.6M
Total Long-Term Assets $11.42M $2.661M $1.968M
Total Assets $96.06M $96.02M $115.5M
YoY Change -22.48% 95.97% 198.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.129M $1.674M $1.031M
YoY Change 247.67% -24.73% -27.95%
Accrued Expenses $7.269M $6.610M $4.002M
YoY Change 47.74% 30.63% 12.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $158.0K $70.00K
YoY Change
Total Short-Term Liabilities $11.21M $9.260M $6.013M
YoY Change 92.66% 27.13% 2.54%
LONG-TERM LIABILITIES
Long-Term Debt $618.0K $298.0K $0.00
YoY Change
Other Long-Term Liabilities $7.218M $0.00 $398.0K
YoY Change 998.63% -100.0% -71.57%
Total Long-Term Liabilities $7.836M $298.0K $398.0K
YoY Change 1092.69% -67.11% -71.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.21M $9.260M $6.013M
Total Long-Term Liabilities $7.836M $298.0K $398.0K
Total Liabilities $18.87M $9.381M $6.236M
YoY Change 199.35% 16.98% -12.17%
SHAREHOLDERS EQUITY
Retained Earnings -$410.1M -$396.9M -$372.3M
YoY Change 12.76% 11.46% 9.97%
Common Stock $29.00K $28.00K $28.00K
YoY Change 154.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.18M $86.64M $109.3M
YoY Change
Total Liabilities & Shareholders Equity $96.06M $96.02M $115.5M
YoY Change -22.48% 95.97% 198.34%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2021 Q4
OPERATING ACTIVITIES
Net Income -$13.20M -$12.40M -$8.559M
YoY Change 72.12% 19.33% 73.61%
Depreciation, Depletion And Amortization $49.00K $63.00K $108.0K
YoY Change -60.16% -49.19% -16.92%
Cash From Operating Activities -$12.28M -$9.117M -$8.086M
YoY Change 7.07% 18.57% 49.74%
INVESTING ACTIVITIES
Capital Expenditures -$426.0K -$53.00K -$18.00K
YoY Change 598.36% -43.01%
Acquisitions
YoY Change
Other Investing Activities $21.08M $10.02M -$49.33M
YoY Change -242.51% -358.62% -1636.76%
Cash From Investing Activities $20.65M $9.971M -$49.35M
YoY Change -239.06% -351.22% -1642.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.013M 39.00K 28.00K
YoY Change -96.41% -96.92% -97.2%
NET CHANGE
Cash From Operating Activities -12.28M -9.117M -8.086M
Cash From Investing Activities 20.65M 9.971M -49.35M
Cash From Financing Activities 3.013M 39.00K 28.00K
Net Change In Cash 11.38M 893.0K -57.41M
YoY Change -80.22% -108.59% 4683.83%
FREE CASH FLOW
Cash From Operating Activities -$12.28M -$9.117M -$8.086M
Capital Expenditures -$426.0K -$53.00K -$18.00K
Free Cash Flow -$11.85M -$9.064M -$8.068M
YoY Change 3.91% 19.33% 49.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001339970
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37378
dei Entity Registrant Name
EntityRegistrantName
ATYR PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3435077
dei Entity Address Address Line1
EntityAddressAddressLine1
3545 John Hopkins Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite #250
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
731-8389
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LIFE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28625046
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8484000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
368000
us-gaap Operating Lease Cost
OperatingLeaseCost
500000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
435000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2336000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
80070000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
105575000
CY2022Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
426000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4375000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5223000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
93355000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
113569000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
733000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
558000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
543000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
827000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1267000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
368000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
175000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
158000
CY2022Q2 us-gaap Assets
Assets
96016000
CY2021Q4 us-gaap Assets
Assets
115537000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1674000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1031000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6610000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4002000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
906000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
980000
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
70000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9260000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6013000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
398000
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
298000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
42500000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28127458
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28127458
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27793035
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27793035
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
28000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
484286000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
481832000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-810000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-263000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396869000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-372296000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109126000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
86635000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
109301000
CY2022Q2 us-gaap Minority Interest
MinorityInterest
-177000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
-175000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
86458000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96016000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115537000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9135000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7655000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18031000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12171000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3449000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2790000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6931000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5476000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
12584000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
10445000
us-gaap Operating Expenses
OperatingExpenses
24962000
us-gaap Operating Expenses
OperatingExpenses
17647000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12584000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10445000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24962000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17647000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
163000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
53000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
387000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
100000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-12421000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-10392000
us-gaap Profit Loss
ProfitLoss
-24575000
us-gaap Profit Loss
ProfitLoss
-17547000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12420000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10391000
us-gaap Net Income Loss
NetIncomeLoss
-24573000
us-gaap Net Income Loss
NetIncomeLoss
-17542000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28063387
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27941560
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28063387
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16128473
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16128473
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27941560
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15121721
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15121721
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-12421000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-10392000
us-gaap Profit Loss
ProfitLoss
-24575000
us-gaap Profit Loss
ProfitLoss
-17547000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-51000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-547000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-12472000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10396000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-25122000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-17565000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-5000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12471000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10395000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25120000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17560000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109126000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1480000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
417000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-496000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12154000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
98374000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000
CY2022Q2 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
34000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
517000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-51000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-12421000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
86458000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31484000
CY2021Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
9621000
CY2021Q1 life Issuance Of Common Stock From Committed Purchase Agreement Net Of Offering Costs
IssuanceOfCommonStockFromCommittedPurchaseAgreementNetOfOfferingCosts
15236000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
360000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-7155000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14760000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2336000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
49532000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000
CY2021Q2 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1265000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
398000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-10392000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
40805000
us-gaap Profit Loss
ProfitLoss
-24575000
us-gaap Profit Loss
ProfitLoss
-17547000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
144000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
244000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
934000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
758000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-434000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-106000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
440000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
411000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
89000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-9000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1949000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-831000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
405000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3108000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1379000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-472000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-414000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19236000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13519000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
96000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
11176000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
40024000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
35700000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
12768000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
169000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24597000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27369000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
5000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
5000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
1514000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
10886000
life Proceeds From Issuance Of Common Stock Through Committed Purchase Agreement Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughCommittedPurchaseAgreementNetOfOfferingCosts
15236000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1520000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26128000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6881000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16952000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9217000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2192000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8484000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2192000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
733000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9217000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2192000
life Purchases Of Property And Equipment In Accounts Payable
PurchasesOfPropertyAndEquipmentInAccountsPayable
143000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
34000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
906000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12400000
us-gaap Net Income Loss
NetIncomeLoss
-24600000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396900000
CY2022Q2 life Cash And Cash Equivalents Restricted Cash And Available For Sale Investments
CashAndCashEquivalentsRestrictedCashAndAvailableForSaleInvestments
89300000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our unaudited condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure for these items in our unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates in our unaudited condensed consolidated financial statements relate to clinical trial and research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</span></p>
us-gaap Operating Lease Cost
OperatingLeaseCost
500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3081458
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1310987
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
80829000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
759000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
80070000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
105788000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
213000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
105575000
CY2020Q1 life Upfront Payment Received
UpfrontPaymentReceived
8000000.0
CY2021Q1 life Milestone Payment Received
MilestonePaymentReceived
2000000.0
CY2020Q1 life Upfront Payment Received
UpfrontPaymentReceived
8000000.0
CY2021Q1 life Milestone Payment Received
MilestonePaymentReceived
2000000.0
CY2021Q1 life Milestone Payment Received
MilestonePaymentReceived
2000000.0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
536000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
404000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
906000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y10M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2022Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
23696
CY2022Q2 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P124M
us-gaap Lessee Operating Lease Lease Not Yet Commenced Option To Extend
LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend
We also have one option to extend the Lease Term for five years.
CY2022Q2 us-gaap Lessee Operating Lease Lease Not Yet Commenced Existence Of Option To Extend
LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend
true
CY2022Q2 us-gaap Lessee Operating Lease Lease Not Yet Commenced Renewal Term1
LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
P5Y
CY2022Q2 life Base Rent Per Square Foot
BaseRentPerSquareFoot
5.75
CY2022Q2 life Annual Upward Adjustments On Base Rate Percentage
AnnualUpwardAdjustmentsOnBaseRatePercentage
0.030
CY2022Q2 us-gaap Tenant Improvements
TenantImprovements
5500000
CY2022Q2 life Additional Allowance For Tenant Improvements
AdditionalAllowanceForTenantImprovements
600000
CY2022Q2 life Base Rent Amortized Percentage
BaseRentAmortizedPercentage
0.080
CY2022Q2 us-gaap Security Deposit
SecurityDeposit
700000
CY2022Q2 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P48M
CY2022Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
49000
CY2022Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
99000
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
99000
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
99000
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
97000
CY2022Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
75000
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
368000
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
70000
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
298000
CY2022Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2022Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0876
CY2021Q1 life Commission Rate Equal To Gross Proceeds1
CommissionRateEqualToGrossProceeds1
0.030
CY2022Q2 life Commission Rate Equal To Gross Proceeds1
CommissionRateEqualToGrossProceeds1
0.030
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4971922
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1412550
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1528444
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.44
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
259
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
13537
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
18.17
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2927198
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.51
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
517000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
398000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
934000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
758000

Files In Submission

Name View Source Status
0000950170-22-017401-index-headers.html Edgar Link pending
0000950170-22-017401-index.html Edgar Link pending
0000950170-22-017401.txt Edgar Link pending
0000950170-22-017401-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
life-20220630.htm Edgar Link pending
life-20220630.xsd Edgar Link pending
life-ex31_1.htm Edgar Link pending
life-ex31_2.htm Edgar Link pending
life-ex32_1.htm Edgar Link pending
life-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
life-20220630_cal.xml Edgar Link unprocessable
life-20220630_def.xml Edgar Link unprocessable
life-20220630_lab.xml Edgar Link unprocessable
life-20220630_pre.xml Edgar Link unprocessable
life-20220630_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable